



Cannabis innovation in the science of life for people and pets

Creso Pharma Limited (ASX:CPH)
Investor Presentation
December 2019

Disclaimer

This presentation has been prepared by Creso Pharma Limited (Company or Creso). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial product advice or advice relating to legal, taxation or investment matters.

This presentation and the information contained herein and all electronic and/or hard copy documentation which comprise it are being provided to you solely for your information and may not be copied, reproduced, distributed, disclosed or published, in whole or in part, to any other person for any purpose whatsoever at any time without the prior written consent of Creso.

This presentation is not an offer to any person nor is it a prospectus.

Creso has prepared this document based on information available to it at the time of preparation. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, options or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecast or projections set out in this presentation.

This presentation is not investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision.

The information contained in this presentation has been prepared without taking into account the objectives, financial situation or needs of individuals.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

To the maximum extent permitted by law, Creso, its related bodies corporate and the officers, directors, employees, advisers and agents of those entities do not accept any responsibility or liability including (but not limited to) any liability arising under the Australian Securities and Investments Commission Act 2001, Corporation Act 2001 or from the fault or negligence on the part of any person, for any loss arising from the use of the presentation or its contents arising in connection with it. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future Matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospectus may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipient's should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US Disclosure

This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 (Securities Act). The Company's shares have not been, and will be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including any exemption for qualified institutional buyers.

Investment highlights

Undervalued

Integrated Value
Chain

Established
Brands

Valuable Revenue
Generating Assets

Global Distribution and
Strategic IP

Greater Customer Universe
Than Just Cannabis

Strong Product
Pipeline

A portfolio approach - Products for people and pets



CRESO
THERAPEUTICS



CRESO
NUTRACEUTICALS



CRESO
ANIMAL HEALTH



CRESO
COSMETICS

Creso Pharma overview

For personal use only

Business Description

- Founded in 2016 and ASX listed on 20 October 2016, trading as “CPH”
- Primarily based in Switzerland (R&D and marketing), with wholly owned cultivation in Canada and Colombia
- Only ASX-listed company with 100% ownership over a Canadian Licensed Producer
- Wholly owned subsidiary Mernova Medical Inc. generating revenues and in advanced stages of securing EU GMP certification
- First to import medicinal cannabis into Australia²
- Innovative pharmaceutical-grade cannabis and hemp product portfolio across four categories and global distribution agreements in place

Financial Snapshot

	AUD
Share Price ³	\$0.145
Shares on Issue	174.1
Market Capitalisation ³	\$25.2
Total Debt Outstanding ⁴	\$3.8
Cash ⁴	\$3.7
Enterprise Value	\$36.2
YTD Revenue ⁵	\$2.8

Share Price Chart¹




Ownership Structure¹

Top 20 Shareholders 52.13%

Top 5 Shareholders

HSBC Custody Nominees (Australia) Ltd	13.26%
Miriam Halperin Wernli	8.25%
International Water Energy Savers Ltd	5.48%
Anglo Australasia Holdings Pty Ltd	4.12%
Citicorp Nominees Pty Ltd	3.10%



The Creso Board – Grounded in business and science

For personal use only



Dr. Miri Halperin Wernli

CEO & CO-FOUNDER

Dr. Halperin Wernli is a senior pharma executive with over 25 years of strategic and operational leadership in global drug and product development in the pharmaceutical and biomedical industries.

She held worldwide executive leadership positions in R&D and in strategic marketing within global pharmaceutical companies in Switzerland and in the US.



Boaz Wachtel

NON-EXECUTIVE CHAIRMAN & CO-FOUNDER

Mr. Wachtel is a leading Medical cannabis expert, co-founder and former managing director of Phytotech Medical (MMJ.ASX), Australia's first publically traded medical cannabis company.

He initiated and helped implement the National Medical Cannabis Program in Israel. Mr. Wachtel is a certified Clinical research manager and holds an MA in management and marketing from the University of Maryland



Adam Blumenthal

NON-EXECUTIVE DIRECTOR & CO-FOUNDER

Mr. Blumenthal has 10 years experience in investment banking and corporate finance. He has deep exposure to Australian and International markets, having provided capital raising and financing solutions to an extensive number of listed and unlisted companies.

He has successfully brought to market several medical cannabis companies spanning Israel, Canada, Switzerland and Australia.



Dr. James Ellingford

NON-EXECUTIVE DIRECTOR

Dr. Ellingford's professional life culminated in being President of an international publicly listed billion dollar business with its headquarters in Geneva, Switzerland and New York, USA.

He has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world.

The Board is backed by a qualified Executive Team

For personal use only



Jorge Wernli

**COMMERCIAL/MARKET ACCESS
DIRECTOR**

Mr Wernli is an expert in Market Access, Pricing Reimbursement & Government Affairs with more than 30 years of experience in Big Pharmaceutical companies Novartis, Wyeth, Vifor and start-ups.

Previously he dealt with and built relationships with Ministries of Health in Europe, South America and selected Asian countries.



Dr. Gian Trepp

**COMMERCIAL/ MARKETING
DIRECTOR**

Dr. Gian Trepp is a senior pharma marketing executive with over 18 years of strategic and operational leadership.

He held worldwide executive leadership positions in General Management and Marketing within global pharmaceutical companies in Switzerland and in the US. He is the founder and owner of GBT Pharma, UK.



Carole Abel

DIRECTOR COMMERCIAL OPERATIONS

Mrs. Carole Abel eMBA has over 20 years of experience in multidisciplinary environments, including 11 years in the pharma industry where she has been successfully leading cross-functional teams and directing groups in different areas: project management, training, process optimization and compliance.

She contributed to the re-organization of departments as well as to inspections/audits preparation.



Chris Hession

**DIRECTOR OF STRATEGIC
PARTNERSHIPS**

Mr. Hession brings over 20 years of commercial experience in the food, beverage and nutraceutical ingredients sectors across the APAC region.

He has held leadership positions with a number of multinational companies and introduced several new ingredients across the APAC region over this time.




Chris Grundy

CHIEF FINANCIAL OFFICER

Mr Grundy is a career CFO with over 30 years' commercial experience in the life sciences sector, in listed and large multinational companies as well as early-stage, rapidly-growing businesses. His experience in other companies includes operational roles in pharmaceutical manufacturing and distribution as CEO and in marketing. He has worked in Australia, the UK and Southern Africa. He qualified as a Chartered Accountant with Ernst & Young.

Key achievements since IPO


For personal use only



● Products
 ● Partnerships
 ● Acquisitions and Financings

Key achievements since IPO

For personal use only



● Products
 ● Partnerships
 ● Acquisitions and Financings

Geographically diversified and vertically integrated

For personal use only

CANADA
Mernova

Facility: 24k sq.ft. Cultivation and processing: Adult Medicinal and Recreational Cannabis

ISRAEL
JV

Facilities: Cultivation, R&D
Licenses: Cultivation
Products: Medicinal
Export: When legalized

LATINAMERICA
Kunna Colombia

Facility: Outdoor Cultivation
Licenses: Cultivation
Products: Medicinal

SWITZERLAND & EU

Facilities: Product development, Manufacturing, commercialization
Products: On sale (Nutraceuticals, Animal Health, Cosmetics)
Export: Worldwide

AUSTRALIA & APAC

Facilities: Admin
Products: Medicinal Cannabis

Current Presence:

-  Therapeutics
-  Animal Health
-  Nutraceuticals
-  Cosmetics

Mernova Medical Inc.

100% owned revenue-generating Canadian LP in advanced stages of securing EU GMP certification



Prime Location

- Facility is located in Nova Scotia, Canada, 60km to Halifax and the airport
- Optimally located to supply to the Canadian, US and European markets

World Class Facilities

- 24,000 sq. ft. facility purpose built to GMP standard, scalable to 200,000 sq. ft.
- Fully automated climate control and irrigation
- 10 grow rooms with total production of 3500kg/year

EU GMP Certification in advanced stage

- In advanced stages of securing EU GMP certification – licence to sell GMP products in the EU
- Once EU GMP certification is received, Creso will be one of only a few Canadian LPs with a licence to export to the EU

Revenue Generating

- First sales to the Canadian domestic market commenced July 2019
- Supply agreement with TerrAscend



*Mernova Medical Inc.
Nova Scotia*

Mernova Medical Inc.

Mernova has a 3-Phase plan for expanding its facility to 200,000 square feet



Exterior of the Mernova Medical cannabis cultivation facility

The world-class facility currently operates at phase 1 of its production capacity

Mernova is positioning itself to become the prime supplier of premium quality CBD and CBD derivatives as the US, European and Canadian markets further mature

Phase 1



10 rooms 1 Tier
3500 Kilos/year
Potential revenue \$15 million

Phase 2



10 Rooms 2 tier
6000 Kilos/year
Potential revenue \$28 million

Phase 3



Building Expansion tbd up to 200,000 sq ft.
Revenue TBD

Team

Bill Fleming - CEO



Mr. Fleming has founded and served as CEO for a number of entrepreneurial companies and has served with senior executive teams dealing with equity and debt financings. He has developed corporate strategies for a wide range of companies, from family-owned businesses to multi-national companies.

Charles Williams – Quality Assurance



Dr. Williams has a Ph.D. in Organic Chemistry from McGill University. He spent four years as an Evaluation Officer in the Health Evaluation Division of the Pest Management Regulatory Agency (PMRA) of Health Canada. He has extensive experience and training in Good Laboratory Practice procedures and requirements, Good Manufacturing Practices and an understanding of the techniques related to the production of pure products.

Kunna S.A.S

Colombia



Wholly owned and debt free Kunna S.A.S. holds a suite of **5 licenses**

In process of registering genetics and acquiring quota

Establishes Creso in the strategically important **Latin American** market, including Argentina, Colombia, Chile, Mexico and Uruguay

Colombia is expected to export more than **40.5 tons** of medicinal cannabis oil by 2019



Kunna S.A.S Current Operations



Cohen Propagation Nurseries Ltd. (JV)

Israel



The JV is converting existing greenhouses into an **IMC-GAP¹** cultivation facility

Will provide **unique therapeutic genetics** developed after years of leading edge Cannabis research

First of its kind strategic partnership in the cultivation of medicinal cannabis in Israel

Cohen is one of the **most experienced agriculture companies in Israel**, established in 1958, with 550 highly trained staff working on 15.7 hectares of greenhouses

Cohen's products are famous for **high quality, sterility and hygiene** and are supplied with a special quality certificate from Israel's Ministry of Agriculture Plant Protection and Inspection Services



*Cohen Propagation Nurseries Ltd
Gderot Operation*

Products for people and pets – A portfolio approach

For personal use only



CRESO THERAPEUTICS

The medicinal cannabis industry is in its infancy and is driven by challenging regulatory policies for access and compliance



CRESO NUTRACEUTICALS

The global nutraceuticals industry now exceeds US\$200bn in sales and continues to grow at a significant pace. Products such as cannaQIX® demonstrate that, with the right knowledge, cannabis and hemp can be used to great consumer benefit in this sector



CRESO ANIMAL HEALTH

Cannabis and hemp are just as effective in animals as in humans due to the shared endocannabinoid system. There exists a significant need for pet complementary feed products targeting animal stress, anxiety and age related ailments



CRESO COSMETICS


Topically applied CBD in analgesics and skin care leverages the body's endocannabinoid system to improve skin health and appearance and deal with muscle injuries, arthritis and osteoarthritis without the use of harsh chemicals

Products with innovative delivery systems

Creso's products have been researched and developed with a focus on innovative methods of delivery

Bioavailability¹

How Effectively Medicine is Absorbed



Buccal
(Absorbed in Mouth)




Topical
(Targeted Muscular Absorption)




Buccal
(Absorbed in Mouth)



Sublingual
(Under the Tongue)



Transdermal
(Through Skin Time Release)



¹ Creso Pharma, Newmeyer MN, et al Clin. Chem. 2016 (<https://www.ncbi.nlm.nih.gov/pubmed/27899456/>), <https://shopatbloom.com/maryland/cannabis-bioavailability-whats-effective-method/>, <https://medium.com/@ericgeisterfer/the-bioavailability-of-medical-marijuana-6d05b712baa0>

Established products and branding:

cannaQIX®50



cannaQIX® 50 is a CBD based broad spectrum hemp oil extract MC product in innovative, non-oil based, buccal lozenge formulation with vitamins and minerals

- No THC
- Prescription Medicine
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Targets chronic pain in humans
- Formulated in a proprietary delivery system maximizing absorption (patent filed)



cannaQIX®50 was launched in:

- New Zealand in Q3 2018
- Brazil in Q2 2019
- Australia in Q4 2019



Established products and branding:

Medicinal CBD Oil

For personal use only



Medicinal CBD Oil is a high-grade therapeutic CBD oil

- No THC
- Prescription Medicine
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Targets chronic pain in humans



Medicinal CBD Oil was launched in New Zealand in Q4 2019



Established products and branding:

cannaQIX®10 NITE



cannaQIX® NITE is a sugar free Food Supplement in innovative buccal formulation containing CBD from broad spectrum hemp oil extract, vitamins, minerals, and lemon balm

- No THC
- OTC
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Targets sleep improvement, stress reduction and support of cognitive and psychological functions in humans
- Formulated in a proprietary delivery system maximizing absorption (patent filed)



cannaQIX®NITE is ready for launch



Established products and branding:

cannAPEAL®



cannAPEAL® is a sugar free Food Supplement in innovative buccal formulation containing organic hemp seed oil and vitamins

- No THC
- OTC
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Targets healthy aging and supports stress reduction in humans
- Formulated in a proprietary delivery system maximizing absorption (patent filed)



cannAPEAL® is planned to be launched in the Middle East, in ASIAPAC and in other countries where CBD is not yet allowed with market introductions in 2020



Established products and branding:

cannaPEAL®



cannaPEAL® NITE is a sugar free Food Supplement in innovative buccal formulation containing organic hemp seed oil, vitamins and lemon balm

- No THC
- OTC
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Targets healthy aging and supports stress reduction in humans
- Formulated in a proprietary delivery system maximizing absorption (patent filed)



cannaPEAL® NITE is planned to be launched in the Middle East, in ASIAPAC and in other countries where CBD is not yet allowed with market introductions in 2020



Established products and branding:

cannaQIX®25




cannaQIX® 25 is a sugar free Food Supplement in innovative buccal formulation containing CBD from broad spectrum hemp oil extract, vitamins and minerals

- No THC
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Targets stress reduction and support of cognitive and psychological functions in humans
- Formulated in a proprietary delivery system maximizing absorption (patent filed)



cannaQIX®25 will be launched in Germany via Multi Level Marketing (MLM) in H1 2020



Established products and branding:

anibidiol® 2.5



anibidiol® 2.5 is a CBD hemp oil-based Complementary Feed for companion animals with CBD from broad spectrum hemp oil in an innovative granular buccal formulation for pets

- No THC
- Distributed by veterinarians
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Targets stress and the strengthening of the immune system
- Formulated in a pet specific proprietary delivery system (patent filed)



anibidiol® 2.5 was launched with Virbac, leader in global animal health, in:

- Switzerland & Liechtenstein in Q4 2017
- Introduced gradually into additional 13 EU countries starting in Q2 2019



EU multi-language packaging (12 languages)



Established products and branding:

anibidiol® 8



anibidiol® 8 is a CBD hemp oil-based Complementary Feed for companion animals with CBD from broad spectrum hemp oil in an innovative granular buccal formulation for pets

- No THC
- Distributed by veterinarians
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Targets chronic pain and the strengthening of the immune system
- Formulated in a pet specific proprietary delivery system (patent filed)



anibidiol® 8 was launched with Virbac, leader in global animal health, in:

- Switzerland & Liechtenstein in Q4 2018
- Introduced gradually into additional 13 EU countries starting in Q2 2019



EU multi-language packaging (12 languages)



Established products and branding:

anibidiol® 80

For personal use only




anibidiol® 80 is a CBD hemp oil-based Complementary Feed for large animals (granules)

- No THC
- Distributed by veterinarians
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Targets chronic pain and the strengthening of the immune system
- Formulated in a pet specific proprietary delivery system (patent filed)



anibidiol® 80 is ready for launch



CRESO
THERAPEUTICS



CRESO
NUTRACEUTICALS



CRESO
ANIMAL HEALTH



CRESO
COSMETICS

Established products and branding:

anibidiol® Oil 500

For personal use only



anibidiol® Oil 500 is a CBD-based Complementary Feed for companion animals with beef aroma

- No THC
- Distributed by veterinarians
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Supports the reduction of stress and chronic pain, and the strengthening of the immune system
- Formulated in a pet specific proprietary delivery system (patent filed)



- anibidiol® Oil 500 is planned to be launched with Virbac in Switzerland in Q1 2020



CRESO
THERAPEUTICS



CRESO
NUTRACEUTICALS



CRESO
ANIMAL HEALTH



CRESO
COSMETICS

Established products and branding:

anibidiol® EQUI



anibidiol® EQUI is a hemp grinded plant material for large animals with CBD and apple flavor

- GAP, GMP compliant
- THC < 0.2%
- “Swiss made” Label
- Targets well-being and re-equilibration of the endocannabinoid system



anibidiol® EQUI is planned to be launched with Virbac in Switzerland in 2020



Established products and branding:

cannaQIX® ORAL CARE



cannaQIX® ORAL CARE is a sugar free Oral Cosmetic in innovative buccal formulation containing CBD, mint, and sage

- No THC
- OTC
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Helps restore oral health - reducing inflammation and supporting the cultivation of healthy oral bacteria
- Formulated in a proprietary delivery system maximizing absorption (patent filed)



cannaQIX® ORAL CARE is ready for launch



Established products and branding:

cannaDOL®

For personal use only



cannaDOL® is a CBD-based functional topical with essential oils

- No THC
- OTC, categorized as Cosmetics
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Addresses the analgesic need in sports-related muscle injuries, arthritis and osteoarthritis




cannaDOL® will be launched in Germany in Q1 2020




Product pipeline and brands

For personal use only



Corporate structure (wholly-owned subsidiaries)

For personal use only



Our compelling investment proposition

Mernova Medical is approaching full growing capacity

Creso Pharma is in advanced stages of securing EU GMP certification for Mernova

Nine new pharma-grade Swiss-Made GMP products are ready for commercial launch

Distribution agreements to be signed in new markets to expand Creso's international product penetration



Creso Pharma's balance sheet has been bolstered by debt and equity funding to allow it to successfully execute its business strategy



Cannabis innovation in the science of life - for people and pets

Creso Pharma Limited (ASX:CPH)
Investor Presentation

Level 24, 300 Barangaroo Avenue
Barangaroo, NSW, 2000, Australia

Alte Steinhäuserstrasse 10,
6330 Cham, Schweiz

www.cresopharma.com

Investor Enquiries
EverBlu Capital
info@everblucapital.com
+61 2 8249 0000

Media Enquiries
Julia Maguire
The Capital Network
julia@thecapitalnetwork.com.au
+61 419 815 386